Cargando…
Unexpectedly durable palliation of metastatic olfactory neuroblastoma using anti-angiogenic therapy with Bevacizumab
Olfactory neuroblastomas (ONBs) are rare malignant tumors that arise from olfactory epithelium and typically present with symptoms attributable to locally invasive disease. Kadish radiographic staging and Hyams' histopathologic grading are prognostic. Overall survival rates, averaging 60–70% at...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PAGEPress Publications
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401161/ https://www.ncbi.nlm.nih.gov/pubmed/22826790 http://dx.doi.org/10.4081/rt.2012.e33 |
_version_ | 1782238576264609792 |
---|---|
author | Dunbar, Erin M. Pumphrey, Phyllis K. Bidari, Sharat |
author_facet | Dunbar, Erin M. Pumphrey, Phyllis K. Bidari, Sharat |
author_sort | Dunbar, Erin M. |
collection | PubMed |
description | Olfactory neuroblastomas (ONBs) are rare malignant tumors that arise from olfactory epithelium and typically present with symptoms attributable to locally invasive disease. Kadish radiographic staging and Hyams' histopathologic grading are prognostic. Overall survival rates, averaging 60–70% at 5 years, remain limited by high rates of delayed loco-regional and distant progression. At initial presentation, the available evidence supports the use of multimodality therapy, historically surgery and radiation, to improve disease-free and overall survival. At recurrence/progression, the available evidence supports the use of therapy to improve disease control and symptoms (palliation), but patient heterogeneity dictates individualization of modalities. Although the ideal use of chemotherapy as a modality remains undefined, the available evidence supports it use, historically platinum-based, for palliation. However, recent insights into the molecular-genetic aberrations of ONBs, coupled with the emergence chemotherapeutic agents capable of targeting such aberrations, suggest an expanded role. The authors report a case of a 60 years-old man, heavily pre-treated for metastatic ONB, presenting with profound central-nerve-system and head-and-neck symptoms. He experienced unexpectedly durable palliation with Bevacizumab anti-angiogenic therapy. Additionally, he experienced localized palliation with an Ommaya reservoir. The authors review the literature regarding historical and emerging therapies for ONB to emphasize the needs for individualization and translational-clinical studies. |
format | Online Article Text |
id | pubmed-3401161 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | PAGEPress Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-34011612012-07-23 Unexpectedly durable palliation of metastatic olfactory neuroblastoma using anti-angiogenic therapy with Bevacizumab Dunbar, Erin M. Pumphrey, Phyllis K. Bidari, Sharat Rare Tumors Case Report Olfactory neuroblastomas (ONBs) are rare malignant tumors that arise from olfactory epithelium and typically present with symptoms attributable to locally invasive disease. Kadish radiographic staging and Hyams' histopathologic grading are prognostic. Overall survival rates, averaging 60–70% at 5 years, remain limited by high rates of delayed loco-regional and distant progression. At initial presentation, the available evidence supports the use of multimodality therapy, historically surgery and radiation, to improve disease-free and overall survival. At recurrence/progression, the available evidence supports the use of therapy to improve disease control and symptoms (palliation), but patient heterogeneity dictates individualization of modalities. Although the ideal use of chemotherapy as a modality remains undefined, the available evidence supports it use, historically platinum-based, for palliation. However, recent insights into the molecular-genetic aberrations of ONBs, coupled with the emergence chemotherapeutic agents capable of targeting such aberrations, suggest an expanded role. The authors report a case of a 60 years-old man, heavily pre-treated for metastatic ONB, presenting with profound central-nerve-system and head-and-neck symptoms. He experienced unexpectedly durable palliation with Bevacizumab anti-angiogenic therapy. Additionally, he experienced localized palliation with an Ommaya reservoir. The authors review the literature regarding historical and emerging therapies for ONB to emphasize the needs for individualization and translational-clinical studies. PAGEPress Publications 2012-06-12 /pmc/articles/PMC3401161/ /pubmed/22826790 http://dx.doi.org/10.4081/rt.2012.e33 Text en ©Copyright E.M. Dunbar et al., 2012 This work is licensed under a Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0). Licensee PAGEPress, Italy |
spellingShingle | Case Report Dunbar, Erin M. Pumphrey, Phyllis K. Bidari, Sharat Unexpectedly durable palliation of metastatic olfactory neuroblastoma using anti-angiogenic therapy with Bevacizumab |
title | Unexpectedly durable palliation of metastatic olfactory neuroblastoma using anti-angiogenic therapy with Bevacizumab |
title_full | Unexpectedly durable palliation of metastatic olfactory neuroblastoma using anti-angiogenic therapy with Bevacizumab |
title_fullStr | Unexpectedly durable palliation of metastatic olfactory neuroblastoma using anti-angiogenic therapy with Bevacizumab |
title_full_unstemmed | Unexpectedly durable palliation of metastatic olfactory neuroblastoma using anti-angiogenic therapy with Bevacizumab |
title_short | Unexpectedly durable palliation of metastatic olfactory neuroblastoma using anti-angiogenic therapy with Bevacizumab |
title_sort | unexpectedly durable palliation of metastatic olfactory neuroblastoma using anti-angiogenic therapy with bevacizumab |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401161/ https://www.ncbi.nlm.nih.gov/pubmed/22826790 http://dx.doi.org/10.4081/rt.2012.e33 |
work_keys_str_mv | AT dunbarerinm unexpectedlydurablepalliationofmetastaticolfactoryneuroblastomausingantiangiogenictherapywithbevacizumab AT pumphreyphyllisk unexpectedlydurablepalliationofmetastaticolfactoryneuroblastomausingantiangiogenictherapywithbevacizumab AT bidarisharat unexpectedlydurablepalliationofmetastaticolfactoryneuroblastomausingantiangiogenictherapywithbevacizumab |